secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001493152-26-013879
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA reports OS >2 years for 8 NSCLC patients; 1 at 33 months in 3L
-------------------------------------------------------------------

- Eight patients treated with ateganosine + cemiplimab in Phase 2 THIO-101 trial had overall survival exceeding 24 months.
- One 3rd-line patient survived 33 months vs. expected 5.8 months; four 2nd-line patients survived >30 months vs. SOC 10.5 months.
- All patients had failed prior checkpoint inhibitor therapy; 5 of 8 patients have ongoing survival follow-up.
- Phase 3 pivotal trial and Part C expansion (up to 48 patients in Asia/Europe) are enrolling.
- Press release references a $50B+ global immunotherapy market as target opportunity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000149315226013879/0001493152-26-013879-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000149315226013879/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-013879

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer